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Abstract
Background: Hypertension remains a significant modifiable risk factor for cardiovascular diseases and a major
determinant of morbidity and mortality. We aimed to describe sex-stratified age-standardized estimates of
prevalence, awareness, treatment and control of hypertension, and their associated factors in older adults.
Methods: The KORA-Age1 is a population-based cross-sectional survey carried out in 2008/2009 on individuals
aged 65–94 years in Augsburg region, Germany. Blood pressure measurements were available for 1052 out of 1079
persons who participated in the physical examination. Factors associated with prevalence, awareness and control of
hypertension were investigated by multivariable logistic regression.
Results: The overall prevalence of hypertension (≥140/90 mmHg) was 73.8% [95% confidence interval (CI), 69.3–
77.9], representing 74.8% (95% CI, 68.4–80.2) in men and 73.5% (95% CI, 66.8–79.3) in women. Among those with
hypertension, 80.2% (95% CI, 75.3–84.4) were aware of their hypertensive condition and 74.4% (95% CI, 69.2–79.1)
were on treatment for hypertension. Among those aware of their hypertension status, 92.8% (95% CI, 88.8–95.6)
were on treatment and 53.7% (95% CI, 47.0–60.1) had their blood pressure controlled. Hypertension was more
frequent in individuals who were older, obese, or had diabetes. Higher education attainment or presence of
comorbidities was associated with higher level of hypertension awareness. Individuals taking three antihypertensive
drug classes were more likely to have controlled hypertension compared with those taking one antihypertensive
drug class, odds ratio (OR), 1.85 (95% CI, 1.14–2.99).
Conclusion: Our findings identified high prevalence of hypertension and relevant health gaps on awareness,
treatment and suboptimal control of hypertension in older adults in Germany. Screening for hypertension should
especially target older adults with low educational attainment and ‘healthy’ elderly with less contact to physicians.
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Background
Cardiovascular diseases (CVDs) are a leading cause of pre-
mature death and morbidity, and a major global public
health concern [1]. In 2016, it was estimated that 17.9 mil-
lion people died from CVDs, which represented 31% of
all-cause mortality in that year [2]. Hypertension is widely
recognized as the most significant modifiable risk factor
for CVDs [3], and a leading contributor of disability-
adjusted life years [4]. Moreover, hypertension remains a
significant concern for public health systems due to the
high prevalence of its associated risk factors. Physical in-
activity, alcohol consumption, smoking, and poor dietary
habits are highly prevalent in the general population, yet
have a lifelong bearing on the risk of hypertension [5].
The incidence of hypertension significantly rises with in-
creasing age [6, 7]; hence, it is more prevalent among older
adults than in young and middle-aged population [4]. Nu-
merous population-based surveys in various regions of the
world estimate that 7 out of 10 adults, 65 years and older,
have been diagnosed with elevated blood pressure [8–10].
This trend is likely to persist, as the population of older per-
sons in high-income countries continues to grow [11]. In
some countries such as the U.S., even though the trends in
incidence of hypertension have only slightly changed [12],
the absolute number of people with hypertension is ever
growing due to the aging population [13]. Some studies ob-
served that about 24–30% of older adults with hypertension
were not aware of their hypertension status [9, 14, 15], and
about 32% were not on treatment [9, 15]. In the same stud-
ies, the proportion of treated and controlled hypertension
was barely 50% [9, 14, 15], which suggests that treatment
and controlled hypertension in older adults is suboptimal
— and an issue of great public health interest. In Germany,
epidemiological studies on prevalence, awareness, treat-
ment and control of hypertension have only been con-
ducted in adults aged 18–79 years [16], but so far not in the
very old population. Therefore, the aim of this study is to
determine the prevalence, awareness, treatment and control
of hypertension, and their associated factors in older people
aged 65–94 years from the general population in Germany.
Methods
Study design and population
The KORA-Age1 study was carried out in 2008/2009
within the framework of the multidisciplinary Coopera-
tive Health Research in the Augsburg Region (KORA)
on individuals aged 65–94 [17]. Briefly, 5991 persons of
the previous four KORA surveys conducted between
1985 and 2001, who were born in 1943 or earlier, still
alive and living in the study region, were mailed a brief
self-administered questionnaire between November 2008
and September 2009. Furthermore, an extended tele-
phone interview was conducted on 4127 study partici-
pants to collect more specific data on morbidity and
health status (e.g., kidney and heart diseases). A sex- and
age-stratified subsample (100 persons per stratum) of
2005 persons were invited for physical examination (e.g.,
blood pressure measurements); 1079 (53.8%) participated,
and of these, 963 persons were examined at the KORA
study center, 94 were examined during a home visit, and
22 got only a short interview [15]. Detailed information on
study design and sampling is provided elsewhere [18, 19].
Study variables
Measurement of blood pressure and anti-hypertensive
medications
Three blood pressure measurements were performed on
the right arm (after a rest of at least 5min), within an
interval of 3min, in a seated position using an automatic
digital oscillometer (HEM 705CP-II Omron Corporation
Japan). Cuffs were adjusted appropriately for arm girth of
the participant. The mean of the second and third mea-
surements was determined and adopted as the blood pres-
sure reading for the present study. All blood pressure
measurements were performed on a single occasion.
All participants were requested to provide medications
used within the last 7 days preceding the examination ap-
pointment. Medications in KORA studies were assigned as
‘antihypertensive medications’ only if the compounds taken
were classified by the most recent guidelines of the German
Hypertension Society [20]. In addition, categorization by an-
tihypertensive drug classes based on the German anatomic
therapeutic chemical (ATC) classification was used for the
following: diuretics (C03, C02L, C07B-C07D, C08G, C09BA
or C09DA), beta blockers (C07), angiotensin converting en-
zyme (ACE) inhibitors (C09A or C09B), angiotensin recep-
tor blockers (ARBs) (C09C or C09D), renin-inhibitors
(C09XA), calcium channel blockers (CCBs) (C08, C07FB22,
C09BB or C09DB) and other antihypertensives (CO2 with-
out C02KX, C02KP (phytotherapy) and C02KH (homeo-
pathy or anthroposophy)).
Definitions
The study adopted widely recognized standard defini-
tions for the study outcomes, namely hypertension,
awareness, treatment, and control of hypertension.
Hypertension
Participants were identified as hypertensive if they had
systolic blood pressure (SBP) ≥ 140 mmHg or diastolic
blood pressure (DBP) ≥90 mmHg or their blood pressure
was controlled as a result of taking antihypertensive
medications. Since these medications may also be indi-
cated for health conditions other than hypertension, in-
formation on antihypertensive medication use was only
utilized for identifying hypertensive cases if the person
confirmed to be aware of hypertension. Similar approach
is applied in other studies in Germany [5, 21].
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Awareness
Individuals with hypertension who responded with “yes” to
the following question: “have you ever been diagnosed by a
doctor or health professional with elevated blood pressure?”
were considered as being aware of their hypertension.
Treatment
Hypertensives aware of their hypertension diagnosis,
who were on at least one of the antihypertensive medi-
cations as identified above.
Control
Treated hypertensives who at the time of measurements
had their blood pressure below the target goals i.e.
SBP < 140mmHg and DBP < 90mmHg.
Special patient groups
Stronger blood pressure target goals for high-risk patient
groups such as diabetes are recommended in some
guidelines [22]. In a subgroup analysis considering this
group, controlled hypertension was defined as blood
pressure below or equal to 130/80 mmHg [22].
Covariates
Besides age and sex, the following covariates were consid-
ered and described in detail. Educational attainment levels
were classified according to highest academic qualification,
namely low level (‘Hauptschule’), middle level (‘Realschule’),
high level (‘Abitur’ or higher level). Smoking status was cat-
egorized into current smoker (for individuals who smoke
regularly or irregularly), former smokers, and never
smokers. Height and weight of participants were measured
during physical examination, and the body mass index
(BMI) calculated by dividing weight by height squared (kg/
m2), and classified according to the World Health
Organization (WHO) guidelines: underweight: < 18.5, nor-
mal ≥18.5 and < 25, overweight ≥25 and < 30, and obese
≥30. Additionally, physical activity was assessed using stan-
dardized interviews in which participants reported their
weekly leisure-time physical activity during summer and
winter. Those who reported almost no sports activity or
about 1 h per week irregularly, were grouped as inactive.
Participants who reported leisure-time physical activity of
1 h or more per week regularly in winter and summer, were
grouped as active. Comorbidity status of participants was
self-reported for specific conditions such as heart and kid-
ney diseases, diabetes mellitus, previous stroke, and cancer
diagnosis in the last 3 years. For diabetes mellitus, use of
antidiabetic medications (A10) additionally contributed to
the final allocation as diabetic person. If participant was
unable to answer interview questions, a proxy interview
was conducted.
Statistical analyses
Descriptive statistical analyses were performed to
characterize the distribution of blood pressure, antihyper-
tensive medication and drug classes, and to determine the
prevalence, awareness, treatment and control of hyperten-
sion. Estimates of these study outcomes (per 100 persons)
were age-standardized using the German population as on
31.12.2009. 10-year age groups were created and population
weights for each group determined. Since a specific popula-
tion weight for individuals aged above 90 years was not
available, the nearest population weight (85 years and
above) was used. To explore group differences between in-
dividuals with hypertension and those without, student t-
tests and Mann–Whitney U tests were applied appro-
priately on continuous variables, and chi-squared test on
categorical variables. Association of covariates and the
prevalence, awareness, treatment and control of hyperten-
sion were explored using logistic regression analyses. In de-
veloping the logistic regression models, four dependent
variables were identified: hypertension status among all
participants (yes = 1, no = 0), awareness among hyperten-
sive individuals (aware = 1, unaware = 0), treatment among
aware hypertensives (treated =1, untreated =0), and control
of blood pressure among treated hypertensives (con-
trolled = 1, uncontrolled = 0). This analysis approach is re-
ported in other studies [7, 14, 15, 23]. Since there was no
significant interaction between sex and the four dependent
variables (p < 0.05), the logistic regression models were not
stratified by sex. Purposeful selection of covariates for
building multivariable logistic regression models was con-
ducted, beginning with univariate analysis, each covariate at
a time [24]. Covariates were included in multivariable
models if univariate analysis showed level of significance of
p-value < 0.25 [24] or if they are documented in literature
as potential confounders. Analyses of variance and likeli-
hood ratio tests were also performed on the adjusted multi-
variable models. The “treatment among aware” model
(treated = 601, untreated =37) was dropped due to the small
sample size of the untreated group in terms of events per
variable (EPV), which showed poor predictive performance.
The acceptability of the multivariable models was evaluated
using the Pearson-Chi-Square goodness of fit test. P-values
< 0.05 were considered statistically significant. The R pro-
gram 3.2.3 was used to conduct the analyses.
Results
Out of the 1079 physically examined study partici-
pants, blood pressure measurements were available
for 1052 persons, representing 50.3% men and 49.7%
women. Out of these, 790 participants were identified
as hypertensive (397 males and 393 females), repre-
senting unweighted prevalence of 75.1%. Table 1 sum-
marizes the demographic and clinical characteristics
of the population stratified by hypertension status.
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The participants’ age ranged between 65 and 94 years,
with mean age of 75.9 years (SD = 6.6). There was a
significant age difference between hypertensives and
non-hypertensives, representing means of 76.2 (SD =
6.4) and 75.1 (6.9) years respectively (p = 0.020). Add-
itionally, there were significant differences in the BMI
for participants with hypertension who had a median
BMI of 28.3 (IQR = 25.8–31.2) compared to 26.9
(IQR = 24.8–29.5) in those without hypertension (p <
0.001). There was a significantly higher frequency of
obesity and diabetes in individuals with hypertension
compared to those without hypertension, representing
a 34.1% vs. 20.6%, p < 0.001 and 21.2% vs. 7.6%, p < 0.001,
respectively.
Prevalence, awareness, treatment and control of
hypertension
Figure 1 provides a schematic representation of the fre-
quency, awareness, treatment, and control of hyperten-
sion in the KORA Age-1 study.
As summarized in Table 2, the overall age-standardized
prevalence of hypertension was 73.8% (95% CI: 69.3–77.9),
Table 1 Characteristics of the study participants stratified by hypertension status
Variable Total (n = 1052) Hypertension (n = 790) No Hypertension (n = 262) P-value†
Sex 1.000
Male 529 (50.3) 397 (50.3) 132 (50.4)
Female 523 (49.7) 393 (49.7) 130 (49.6)
Age (mean (±SD)) 75.9 (6.6) 76.2 (6.4) 75.1 (6.9) 0.020
Age (years) (%) 0.020
65–69 227 (21.6) 157 (19.9) 70 (26.7)
70–74 227 (21.6) 163 (20.6) 64 (24.4)
75–79 241 (22.9) 192 (24.3) 49 (18.7)
80–84 232 (22.1) 186 (23.5) 46 (17.6)
85–94 125 (11.9) 92 (11.6) 33 (12.6)
Living with partner (%) 656 (63.0) 420 (79.7) 236 (45.9) < 0.001
Smoking status (%) < 0.001
Never 565 (53.7) 417 (52.8) 148 (56.5) 0.504
Ex-smoker 438 (41.6) 337 (42.7) 101 (38.5)
Current smoker 49 (4.7) 36 (4.6) 13 (5.0)
Education a (%) 0.112
Low level 717 (68.2) 552 (69.9) 165 (63.0)
Middle level 190 (18.1) 136 (17.2) 54 (20.6)
High level 145 (13.8) 102 (12.9) 43 (16.4)
BMI (kg/m2) (%) < 0.001
Underweight (< 18.5) 1 (0.1) 0 (0.0) 1 (0.4)
Normal (18.5–24.9) 213 (20.2) 142 (18.0) 71 (27.1)
Overweight (25–29.9) 515 (49.0) 379 (48.0) 136 (51.9)
Obese (≥30) 323 (30.7) 269 (34.1) 54 (20.6)
BMI (median (IQR)) 27.9 (25.4–30.8) 28.3 (25.8–31.2) 26.9 (24.8–29.5) < 0.001
Physically active (%) b 561 (53.3) 422 (53.4) 139 (53.1) 0.975
Heart diseases (%) * 327 (31.1) 250 (31.6) 77 (29.4) 0.544
Kidney diseases (%) * 50 (4.8) 42 (5.3) 8 (3.1) 0.185
Diabetes (%) c 187 (17.8) 167 (21.2) 20 (7.6) < 0.001
Stroke (%) * 88 (8.4) 68 (8.6) 20 (7.6) 0.715
†p value obtained from comparing differences between hypertensives and non-hypertensives using X2-test for categorical variables, t-test for age difference, and
Mann-Whitney U test for BMI medians
a Based on the highest academic qualification: Low level (‘Hauptschule’), Middle level (‘Realschule’), High level (‘Abitur’ or higher level)
b Physical activity: self-reported sporting activity during leisure time of 1 h or more per week, regularly or irregularly
c Diabetes mellitus was both self-reported and confirmed also through use of antidiabetic medications
* Self-reported comorbidities
SD Standard deviation of the observed age in our sample; BMI Body mass index; IQR Interquartile range
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with men having slightly higher prevalence of
hypertension than women (74.8% vs. 73.5%). The
frequency of hypertension was lowest in the group
65–74 years with 70.5% (95% CI: 66.0–74.6) and
highest in participants aged 75–84 years with 79.9%
(95% CI: 76.0–83.4). Among individuals with hyper-
tension (n = 790), 80.2% (95% CI: 75.3–84.4) af-
firmed having been diagnosed with hypertension;
hence, were considered as being aware of their
hypertension status. The level of awareness in-
creased gradually with age, and was higher in
women than in men (81.3% vs. 78.3%).
Overall, in individuals with hypertension, 74.4%
(95% CI: 69.2–79.1) were on antihypertensive treat-
ment, and the frequency of treated hypertension in-
creased with age. However, considering treatment
only among those aware of their status, 92.8% (95%
CI, 88.8–95.6) were on antihypertensive medication,
and 53.7% (95% CI: 47.0–60.1) of the treated hypertensives
had attained blood pressure below 140/90mmHg. The
frequency of optimal blood pressure control slightly de-
clined with age, and was lowest in the oldest group, 49.3%
(95% CI: 37.7–61.0).
The distribution of SBP and DBP by 5-year age groups
is summarized in Fig. 2. The oldest group, 85–94 years,
had the highest SBP mean of 146.8 mmHg, but had the
lowest DBP mean of 73.3 mmHg.
Results of multivariable analysis of factors associated with
prevalence, awareness and control of hypertension
The results of the multivariable logistic models are sum-
marized in Table 3. Briefly, the prevalence of hyperten-
sion increased with increasing age for age group 75–79
years (OR 1.79, 95% CI: 1.11–2.72), and for age group
80–84 years (OR 1.95, 95% CI: 1.22–3.12), and declined
beyond the age of 85 years, (OR 1.41, 95% CI: 0.80–
2.47), p = 0.2337 in comparison to age group 65–69
years. There was higher frequency of hypertension in in-
dividuals with obesity compared with those with normal
weight (OR 2.14, 95% CI: 1.39–3.29). Individuals with
diabetes were also more likely to have hypertension
compared to non-diabetic persons (OR 2.82, 95% CI:
1.70–4.70). There were no statistically significant differ-
ences in hypertension prevalence with respect to other
sociodemographic characteristics such as sex, living with
partner, education attainment, and lifestyle factors such
as smoking status and physical activity.
The level of education had significant influence on
awareness status. Individuals with the highest educa-
tional attainment were more likely to be aware of their
blood pressure status compared to individuals with low
education (OR 2.40, 95% CI: 1.20–4.80). Having comor-
bidities was also associated with higher odds of being
aware: obesity (OR 1.97, 95% CI: 1.14–3.42), heart dis-
ease (OR 2.38, 95% CI: 1.46–3.87), stroke (OR 4.45, 95%
Fig. 1 Flow diagram showing the frequency, awareness, treatment and control of hypertension in KORA-Age 1 study
Table 2 Prevalence, awareness, treatment and control of hypertension by age and sex
Age (years) Prevalence (n = 1052) Awareness (n = 790) Treatment among aware
hypertensives (n = 638)
Control among treated
(n = 601)
Male 65–94 74.8 (68.4–80.2) a 78.3 (71.1–84.2) a 93.9 (87.9–97.1) a 52.5 (43.2–61.5) a
Female 65–94 73.5 (66.8–79.3) a 81.3 (74.0–87.0) a 92.6 (86.1–96.4) a 54.9 (45.3–64.2) a
Total 65–74 70.5 (66.0–74.6) 78.4 (73.5–82.7) 90.8 (86.4–93.9) 54.4 (47.7–60.9)
75–84 79.9 (76.0–83.4) 82.0 (77.7–85.7) 96.1 (93.2–97.8) 53.0 (47.2–58.8)
85–94 73.6 (64.8–80.9) 83.7 (74.2–90.3) 97.4 (90.1–99.5) 49.3 (37.7–61.0)
65–94 73.8 (69.3–77.9) a 80.2 (75.3–84.4) a 92.8 (88.8–95.6) a 53.7 (47.0–60.2) a
aAge-standardized according to the distribution of the Germany population, 31 December 2009
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CI: 1.36–14.62), and diabetes (OR 2.05, 95% CI: 1.17–
3.58), compared to individuals without the respective
comorbid status.
There were no statistically significant differences with
respect to sociodemographic characteristics or presence
of comorbidities and control of blood pressure. How-
ever, treated hypertensives were more likely to have con-
trolled blood pressure if under three antihypertensive
drug classes (OR 1.85, 95% CI: 1.14–2.98) compared to
those on monotherapy. Taking more than three antihy-
pertensive drug classes was not associated with statisti-
cally significant higher odds of being controlled (OR
1.24, 95% CI: 0.68–2.27), p = 0.490 compared to
monotherapy.
Diabetes and blood pressure control
Multivariable adjusted regression analysis considering
controlled hypertension among diabetic individuals as
blood pressure ≤ 130/80mmHg, showed that treated hy-
pertensives with diabetes were less likely to have con-
trolled blood pressure (OR 0.38, 95% CI: 0.25–0.58)
compared to non-diabetic hypertensives. As shown in
Table 3, there was no statistically significant change in
the rest of covariates of the hypertension control model.
Discussion
This study showed that the prevalence of hypertension
in adults aged 65–94 years was 73.8%, translating to 3
out of 4 older adults having high blood pressure. The
age-standardized prevalence of hypertension was slightly
higher in men than women, and increased with age.
Even though our data showed highest SBP in individuals
aged 85–94 years, a guarded approach in clinical inter-
pretation of these findings should be considered. Unlike
in the middle-aged persons, high SBP in the very elderly
(> 85 years) is not consistently associated with increased
risk for CVD events [24, 25].
Being aware of one’s hypertension status may be a mo-
tivation for positive lifestyle modification: increasing
physical activity, moderating alcohol consumption,
smoking cessation, and dietary changes. Since 80.2% of
hypertensive persons in this study were aware of their
hypertension status, and 92.8% of those aware were on
treatment, this suggests that the burden of untreated
hypertension might be attributed to lack of awareness.
Considering evidence that treating hypertension in older
persons markedly reduces the risk of cardiovascular
complications and mortality [25], intensifying screening
of hypertension in the elderly should therefore, be
encouraged.
The present study showed that the proportion of
controlled hypertension in the older German popula-
tion is quite low – 53.7%. We however, hypothesized
that measuring blood pressure on a single occasion
potentially underestimated the proportion of con-
trolled hypertension. A 24-h ambulatory blood pres-
sure monitoring, though hardly ever used in
population-based observational studies, may detect
Fig. 2 Distribution of systolic and diastolic blood pressure by 5-year age groups among hypertensives (n = 790). Abbreviations: DBP – Diastolic
blood pressure, SBP – systolic blood pressure
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fluctuations in blood pressure and other symptoms in
treated hypertensive subjects [13]. Our observations
could also indicate a high prevalence of resistant
hypertension in the population. In part, this may be
due to non-adherence to treatment, which is common
in older individuals [13]. Moreover, drug induced
elevation of blood pressure was not evaluated in our
study. It should be noted that some medications such
as nonsteroidal anti-inflammatory drugs (NSAIDs) sig-
nificantly elevate blood pressure [26] and have been
shown to destabilize the effect of main classes of anti-
hypertensive drugs [27].
Table 3 Results of the multivariable logistic regression models on factors associated with prevalence, awareness and control of
hypertension
Characteristics/variables Prevalence (n = 1039) Awareness (n = 780) Control (n = 595) Controlc (n = 595)
ORa (95%, CI) ORa (95%, CI) ORa (95%, CI) ORa (95%, CI)
Sex (ref: Men) 1 1 1 1
Women 1.11 (0.79–1.56) 1.21 (0.78–1.90) 1.00 (0.66–1.49) 1.03 (0.36–1.96)
Age Groups (years) (ref: ≥65–69) 1 1 1 1
70–74 1.09 (0.72–1.67) 1.12 (0.64–1.96) 1.20 (0.70–2.06) 0.97 (0.56–1.68)
75–79 1.79 (1.11–2.72) * 1.12 (0.64–1.95) 1.18 (0.69–2.02) 0.97 (0.57–1.66)
80–84 1.95 (1.22–3.12) ** 1.19 (0.66–2.15) 0.91 (0.53–1.56) 0.70 (0.40–1.21)
85–94 1.41 (0.80–2.47) 1.26 (0.59–2.69) 0.81 (0.42–1.58) 0.78 (0.40–1.54)
Living with Partner (ref: No) 1 1 1 1
Yes 1.01 (0.72–1.41) 0.94 (0.61–1.46) 0.93 (0.63–1.37) 0.83 (0.56–1.54)
Education (ref: Low) 1 1 1 1
Middle level 0.88 (0.60–1.29) 1.58 (0.93–2.66) 1.55 (0.98–2.44) 1.59 (1.01–2.51) *
High level 0.78 (0.51–1.18) 2.40 (1.20–4.80) * 0.84 (0.51–1.37) 0.91 (0.55–1.51)
Smoking Status (ref: Never) 1 1 1 1
Ex-smoker 1.19 (0.86–1.65) 0.76 (0.50–1.16) 1.19 (0.82–1.74) 1.12 (0.76–1.64)
Current smoker 1.21 (0.59–2.49) 0.58 (0.24–1.38) 2.31 (0.90–5.92) 2.36 (0.93–5.99)
BMI (ref: Normal) 1 1 1 1
Underweight (< 18.5) b 0.00 (0.00 - ∞) – – –
Overweight (25–30) 1.33 (0.93–1.91) 1.44 (0.88–2.36) 0.81 (0.50–1.34) 0.87 (0.53–1.43)
Obese (≥30) 2.14 (1.39–3.29) *** 1.97 (1.14–3.42) * 1.02 (0.61–1.73) 1.09 (0.64–1.85)
Physical Activity (ref: No) 1 1 1 1
Yes 1.26 (0.92–1.72) 0.85 (0.57–1.27) 0.89 (0.63–1.26) 1.04 (0.73–1.48)
Heart Disease (ref: No) 1 1 1 1
Yes 0.94 (0.68–1.31) 2.38 (1.46–3.87) *** 1.19 (0.83–1.72) 1.35 (0.93–1.97)
Stroke (ref: No) 1 1 1 1
Yes 1.01 (0.58–1.75) 4.45 (1.36–14.62) * 0.99 (0.57–1.73) 0.95 (0.54–1.67)
Kidney disease (ref: No) 1 1 1 1
Yes 1.94 (0.88–4.30) 1.85 (0.62–5.48) 1.31 (0.64–2.71) 1.02 (0.49–2.12)
Diabetes (ref: No) 1 1 1 1
Yes 2.82 (1.70–4.70) *** 2.05 (1.17–3.58) * 0.86 (0.57–1.29) 0.38 (0.25–0.58) ***
Drug combinationsc (ref: [1]) – – 1 1
2 classes – – 1.35 (0.85–2.12) 1.32 (0.83–2.09)
3 classes – – 1.85 (1.14–2.99) * 1.90 (1.17–3.10) **
≥ 4 classes – – 1.24 (0.68–2.27) 1.22 (0.66–2.27)
Abbreviations: CI Confidence interval; OR Odds ratio; BMI Body mass index expressed as kg/m2;
*p value < 0.05; **p values < 0.01; ***p value < 0.001
aThe odds ratio from multivariable logistic regression, adjusted for other variables in the table
b only one individual was underweight and was observed to be non-hypertensive. The OR for this category is therefore, unreliable
c Subgroup analysis in which controlled hypertension was defined as blood pressure ≤ 130/80 mmHg for individuals with diabetes mellitus
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Factors associated with prevalence, awareness, and control
of hypertension
The odds ratios for the prevalence of hypertension as
shown in Table 3, suggests that the frequency of hyper-
tension gradually increased with increasing age up to the
age of 84 years, then declined with further ages. Other
studies in comparable settings have reported similar ob-
servations [15, 23, 28]. Individuals who reach a very old
age above 85 years are generally healthier, and this may
explain the declining prevalence of hypertension in the
oldest age group.
Obese individuals were about twice more likely to have
hypertension compared to those with healthy weight.
Numerous studies have reported higher frequency of
hypertension in overweight and obese subjects [9, 15, 23,
28]. However, even though obesity may be an independ-
ent predictor of hypertension, there is potential inter-
action with other lifestyle factors such as physical
activity and dietary habits.
Expectedly, individuals with high education attainment
had more than twice higher odds of being aware of their
hypertension status than those with low education. Edu-
cation is a well elucidated determinant of health dispar-
ity, and such disparities have been shown to be more
pronounced in later life phases [29]. Our findings under-
score the need to target individuals with low educational
attainment for hypertension screening and treatment.
There was also a higher level of awareness in individ-
uals with other comorbidities such as obesity, heart dis-
eases, stroke, and diabetes. These findings are consistent
with other studies [15, 23, 28]. We considered that indi-
viduals with these comorbidities are more likely to have
higher frequency visits to their treating physicians and
are preferentially screened for hypertension.
The poor control of hypertension as observed in our
study reflects difficulties in blood pressure control in
later life phases, and similar findings have been reported
in other studies [9, 14, 23, 28]. Hypertensive participants
who were taking multiple drug classes were more likely
to attain blood pressure control targets compared to indi-
viduals on a single antihypertensive drug class. Beyond
three combinations, further clinical effect was not statis-
tically significant. It could be interpreted that individuals
who were taking more than three antihypertensive drug
classes probably had advanced hypertension or resistant
hypertension that was more difficult to be controlled by
treatment. These findings are supported by a recent clin-
ical trial, that reported better control of blood pressure
in individuals treated with more than one antihyperten-
sive drug class as initiation therapy compared to those
treated with single drug class or stepped-care approach
[30]. The European Society of Hypertension (ESH) 2018
guidelines recently recognized that, monotherapy treat-
ment approach was generally ineffective for high risk
hypertensive patient groups – those in grade 2 and 3
hypertension – and recommends multiple antihyperten-
sive drug treatment, starting with two antihypertensive
drug classes and up-titrating to three antihypertensive
drug classes when hypertension control goals are not
attained [31]. However, it should be emphasized that
treatment goals for hypertension in the elderly poses sig-
nificant challenges due to age-related physiological alter-
ations, frailty and presence of multiple comorbidities
[11, 32], and adverse health events associated with poly-
pharmacy [33]. As such, individualized treatment strat-
egy for the elderly is encouraged due to their special
health conditions.
When blood pressure cut-off points for patients with
diabetes were considered – as demonstrated in the sub-
group analysis model – individuals with diabetes were
shown to have significant difficulties with blood pressure
control compared to non-diabetic individuals. Poor
control of blood pressure among diabetic individuals is
documented in other epidemiological studies [15, 23].
Several complex and inter-related biological changes
may explain this potential resistance to antihypertensive
drugs. Diabetes, which is believed to exacerbate stiffen-
ing of arteries, is also associated with higher risk of renal
impairment and cardiovascular complications [34].
These complications have negative implications on
blood pressure control. Moreover, volume overload
which is commonly reported in persons with diabetes
and associated with diabetic nephropathy, is believed to
cause resistant hypertension [35]. However, other au-
thors posit that difficulties in control of blood pressure
in persons with diabetes maybe a result of inadequate
clinical management, particularly, inadequate and in-
appropriate antihypertensive medication doses, drug
class combinations, and poor compliance [36].
Implications for practice and research
There is need to improve screening of elderly population
groups, especially those with a low level of education
and those perceived to be at high risk of hypertension
due to obesity or diabetes. Early treatment of hyperten-
sion may prevent irreversible arterial damage especially,
in older persons who are at higher risk for vascular in-
jury [5], and reduce risk of stroke and heart attack [25].
It should be noted, however, that treatment of hyperten-
sion especially in the very old, should be considered on
the balance between risk and benefits for individual pa-
tients [11]. Evidence on the ideal blood pressure targets
and safest hypertension regimen for this age group re-
mains inconclusive [11, 25, 37]. Nonetheless, the import-
ance of adequate clinical management of hypertension
including multiple antihypertensive drug treatment espe-
cially in older adults with diabetes should be considered.
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Strengths and limitations
The study methods were highly standardized and
consistent with widely recognized guidelines. As a
population-based study, we recruited noninstitutional-
ized participants and employed comprehensive medica-
tion use review procedures. Our findings are therefore,
plausible and comparable with similar studies. However,
the blood pressure measurements were performed on a
single visit; hence, white-coat hypertension and masked
hypertension could be possible [38]. As a result, there
might be a potential overestimation of prevalence of
hypertension and underestimation of the controlled
hypertension. Moreover, consistent with the general
limitations of cross-sectional studies, the possibility of
residual confounding as well as potential overestimation
of some associations due to use of odds ratios instead of
prevalence ratios [39] cannot be ruled out. Some of our
variables were self-reported and could not be objectively
verified at the time of the study.
Conclusion
Our study identified relevant health gaps on awareness,
treatment and control of hypertension in older people
aged 65–94 years in Germany. Screening for hyperten-
sion would particularly be useful among older adults
with low educational attainment, who were observed to
have low awareness of their hypertension status. Even
though we observed that individuals taking three classes
of antihypertensive drugs were more likely to have con-
trolled hypertension compared to those taking a single
class of antihypertensive drugs, a guarded, more individ-
ualized treatment approach should be considered when
dealing with elderly subjects.
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